0001474064-13-000063.txt : 20130410 0001474064-13-000063.hdr.sgml : 20130410 20130410181904 ACCESSION NUMBER: 0001474064-13-000063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130410 FILED AS OF DATE: 20130410 DATE AS OF CHANGE: 20130410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BESHAR LUKE M CENTRAL INDEX KEY: 0001192128 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 13754648 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE STREET 2: 3RD FLOOR CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2013-04-10 0000890465 NPS PHARMACEUTICALS INC NPSP 0001192128 BESHAR LUKE M 550 HILLS DRIVE BEDMINSTER NJ 07921 0 1 0 0 EVP & CFO Common Stock 2013-04-10 4 M 0 50000 4.05 A 109180 D Common Stock 2013-04-10 4 S 0 50000 12.0044 D 59180 D Stock Option 4.05 2013-04-10 4 M 0 50000 0 D 2017-11-20 Common Stock 50000 100000 D The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 14, 2012. The price shown above represents the weighted average price of the shares sold. The range of sales prices was 12.00 and 12.005. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid. On November 20, 2007, the Reporting Person received a grant of 200,000 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month thereafter. /s/ Luke Beshar, by Edward Stratemeier as attorney-in-fact 2013-04-10